These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 2476668)

  • 1. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene.
    Lavigueur A; Maltby V; Mock D; Rossant J; Pawson T; Bernstein A
    Mol Cell Biol; 1989 Sep; 9(9):3982-91. PubMed ID: 2476668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumorigenic potential of pituitary tumor transforming gene (PTTG) in vivo investigated using a transgenic mouse model, and effects of cross breeding with p53 (+/-) transgenic mice.
    Fong MY; Farghaly H; Kakar SS
    BMC Cancer; 2012 Nov; 12():532. PubMed ID: 23164239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of the cellular p53 gene is a common feature of Friend virus-induced erythroleukemia: relationship of inactivation to dominant transforming alleles.
    Munroe DG; Peacock JW; Benchimol S
    Mol Cell Biol; 1990 Jul; 10(7):3307-13. PubMed ID: 1694008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of lymphomagenic oncogenes in T-cell lymphomas of HPV 16 transgenic mice.
    Yang JT; Liu CZ; Domer P; Iannaccone P
    Cancer Detect Prev; 1998; 22(5):405-15. PubMed ID: 9727621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice.
    Elson A; Deng C; Campos-Torres J; Donehower LA; Leder P
    Oncogene; 1995 Jul; 11(1):181-90. PubMed ID: 7624126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor susceptibility and apoptosis defect in a mouse strain expressing a human p53 transgene.
    Dudgeon C; Kek C; Demidov ON; Saito S; Fernandes K; Diot A; Bourdon JC; Lane DP; Appella E; Fornace AJ; Bulavin DV
    Cancer Res; 2006 Mar; 66(6):2928-36. PubMed ID: 16540640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of p53 transgenic mice in the development of cancer models for multiple purposes.
    Lubet RA; Zhang Z; Wiseman RW; You M
    Exp Lung Res; 2000 Dec; 26(8):581-93. PubMed ID: 11195457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis.
    Jones SN; Hancock AR; Vogel H; Donehower LA; Bradley A
    Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15608-12. PubMed ID: 9861017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CD2-scl transgene alters the phenotype and frequency of T-lymphomas in N-ras transgenic or p53 deficient mice.
    Curtis DJ; Robb L; Strasser A; Begley CG
    Oncogene; 1997 Dec; 15(24):2975-83. PubMed ID: 9416841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation.
    Hinds P; Finlay C; Levine AJ
    J Virol; 1989 Feb; 63(2):739-46. PubMed ID: 2642977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Generation and analyses of transgenic mice containing mutant p53 transgene].
    Hosokawa A
    Fukuoka Igaku Zasshi; 1999 Mar; 90(3):80-7. PubMed ID: 10339928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 transgenic mice: accelerated erythroleukemia induction by Friend virus.
    Lavigueur A; Bernstein A
    Oncogene; 1991 Dec; 6(12):2197-201. PubMed ID: 1766668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The p53 tumor suppressor gene and gene product.
    Levine AJ
    Princess Takamatsu Symp; 1989; 20():221-30. PubMed ID: 2488233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moloney murine leukemia virus-induced lymphomas in p53-deficient mice: overlapping pathways in tumor development?
    Baxter EW; Blyth K; Donehower LA; Cameron ER; Onions DE; Neil JC
    J Virol; 1996 Apr; 70(4):2095-100. PubMed ID: 8642629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A p53 defect sensitizes various stages of B cell development to lymphomagenesis in mice carrying an IgH 3' regulatory region-driven c-myc transgene.
    Fiancette R; Rouaud P; Vincent-Fabert C; Laffleur B; Magnone V; Cogné M; Denizot Y
    J Immunol; 2011 Dec; 187(11):5772-82. PubMed ID: 22039300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integration of Friend murine leukemia virus into both alleles of the p53 oncogene in an erythroleukemic cell line.
    Hicks GG; Mowat M
    J Virol; 1988 Dec; 62(12):4752-5. PubMed ID: 2846884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deletion of 5'-coding sequences of the cellular p53 gene in mouse erythroleukemia: a novel mechanism of oncogene regulation.
    Rovinski B; Munroe D; Peacock J; Mowat M; Bernstein A; Benchimol S
    Mol Cell Biol; 1987 Feb; 7(2):847-53. PubMed ID: 3547084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in heparan sulfate pattern but not in oncogene expression correlate with tumor growth in spontaneous transformation of cells.
    Smith CA; Winterbourne DJ; McFarland VW; Mora PT
    Oncogene Res; 1987; 1(4):325-41. PubMed ID: 2966923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung-specific expression of human mutant p53-273H is associated with a high frequency of lung adenocarcinoma in transgenic mice.
    Duan W; Ding H; Subler MA; Zhu WG; Zhang H; Stoner GD; Windle JJ; Otterson GA; Villalona-Calero MA
    Oncogene; 2002 Nov; 21(51):7831-8. PubMed ID: 12420220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multistage Friend erythroleukemia: independent origin of tumor clones with normal or rearranged p53 cellular oncogenes.
    Chow V; Ben-David Y; Bernstein A; Benchimol S; Mowat M
    J Virol; 1987 Sep; 61(9):2777-81. PubMed ID: 3302314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.